First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the benefits and harms of drugs inhibiting the RAS in patients with elevated blood pressure (>130/85mmHg).